Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Pravigard PAC

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bristol-Myers Squibb's Pravigard PAC clears FDA June 24, making it the first aspirin co-packaged product for reducing the occurrence of serious cardiovascular events. The Pravachol (pravastatin)/buffered aspirin combo will launch in August at the same average wholesale price as Pravachol to discourage patients from purchasing the treatments separately. FDA notes Pravigard PAC's convenience and potential for increased compliance in a June 25 "Talk Paper." BMS also is developing a single tablet version of the combination (1Pharmaceutical Approvals Monthly Aug. 1, 2002, In Brief

Related Content

Pravastatin/aspirin combo





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts